Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service breast biopsy & localization cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 165 | 9,686 | 40% |
| 2020 | 147 | 8,424 | 43% |
| 2021 | 146 | 9,158 | 48% |
| 2022 | 145 | 8,884 | 52% |
| 2023 | 132 | 8,185 | 56% |
| 2024 | 133 | 8,308 | 59% |
| 2025 from claims | – | 8,089 7,423–8,558 | 61% |
| 2026 forecast | – | 8,202 7,217–9,465 | 62% |
| 2027 forecast | – | 8,281 7,079–9,868 | 62% |
| 2028 forecast | – | 8,356 6,972–10,231 | 63% |
| 2029 forecast | – | 8,426 6,882–10,567 | 64% |
| 2030 forecast | – | 8,492 6,803–10,882 | 65% |
Image-guided breast biopsy and marker/localization placement. Professional codes (what the surgeon bills): CPT 19081, 19083, 19085, 19281, 19283, 19285.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 22% of the cases CMS names in North Carolina; 73 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 55% hospital outpatient, 45% office. The share outside the hospital has moved −3 pts since 2019.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 245 | 16,085−0.7%/yr | −0.7%/yr | 7.7 | 39% | 18,600 in 2030+2.5%/yr |
| Texas | 203 | 11,818−2.4%/yr | −2.4%/yr | 5.9 | 24% | 13,700 in 2030+2.5%/yr |
| Virginia | 130 | 7,399−0.8%/yr | −0.8%/yr | 7.4 | 20% | 9,210 in 2030+3.7%/yr |
| Georgia | 103 | 5,906−2.9%/yr | −2.9%/yr | 7.3 | 17% | 6,640 in 2030+2%/yr |
| Maryland | 79 | 5,089−2.2%/yr | −2.2%/yr | 6.0 | 73% | 5,630 in 2030+1.7%/yr |
| Tennessee | 81 | 4,468−4.7%/yr | −4.7%/yr | 6.8 | 31% | 4,740 in 2030+1%/yr |
| South Carolina | 68 | 3,858−2.4%/yr | −2.4%/yr | 6.0 | 11% | 4,310 in 2030+1.8%/yr |
| Kentucky | 49 | 3,005−2.2%/yr | −2.2%/yr | 7.0 | 6% | 3,430 in 2030+2.2%/yr |
| Louisiana | 36 | 2,413−3.9%/yr | −3.9%/yr | 6.3 | 14% | 2,390 in 2030−0.2%/yr |
| Oklahoma | 56 | 2,408+1%/yr | +1%/yr | 5.2 | 2% | 2,580 in 2030+1.1%/yr |
| Alabama | 36 | 2,322−3.8%/yr | −3.8%/yr | 5.7 | 10% | 2,460 in 2030+1%/yr |
| Arkansas | 39 | 2,201−3.4%/yr | −3.4%/yr | 6.2 | 36% | 2,190 in 2030−0.1%/yr |
| District of Columbia | 28 | 1,896+2.5%/yr | +2.5%/yr | 31.6 | 69% | 2,250 in 2030+2.9%/yr |
| Mississippi | 36 | 1,779−6.5%/yr | −6.5%/yr | 5.0 | 22% | 1,620 in 2030−1.5%/yr |
| Delaware | 19 | 1,063−4.7%/yr | −4.7%/yr | 6.5 | 26% | 1,140 in 2030+1.1%/yr |
| West Virginia | 16 | 949−6.7%/yr | −6.7%/yr | 4.9 | 8% | 890 in 2030−1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Tumor & fibroid embolization | 11 | 795+10%/yr | +10%/yr | 0.81.5× | 63% | 1,900 in 2030+16%/yr |
| Tumor ablation | 3 | 334−1.9%/yr | −1.9%/yr | 0.31.1× | 0% | 320 in 2030−0.8%/yr |
Breast biopsy & localization in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Florida
Exact Sciences leads with 59% of company spending on these surgeons in 2025, +18 pts on 2024.
In 2025, 18 companies reported engagement with North Carolina’s surgeons worth $156K in consulting, speaking, meals and travel tied to these products, about $1,173 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 4 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 19081 (bx breast 1st lesion strtctc), commercial plans pay North Carolina’s hospitals a median of $665, from $665 at the lowest to $3,326 at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.